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Enamel matrix derivative in the Treatment of Peri-implant Diseases 
ABSTRACT 
 
Objective: To evaluate the benefit in terms of clinical, histological and radiographic            
outcomes of the adjunctive use of enamel matrix derivative (Emdogain ​®​; Straumann,           
Basel, Switzerland) on the non-surgical and surgical treatment of peri-implant diseases. 
 
Methods: A systematic literature search comprised three databases: PubMed, Scopus          
and Cochrane. Eligible studies were selected based on the inclusion criteria. 
 
Results: Seven studies were selected for data extraction. Two randomized clinical trials            
using Emdogain ​® as an adjuvant for non-surgical treatment of peri-implant mucositis ​;           
tree cohort studies and and two randomized clinical trials using Emdogain ​® as an             
adjuvant for surgical treatment of peri-implantitis. A reduction of the mean bleeding on             
probing (76.6%), probing depth (3.5mm), ​P. gingivalis counts and ​mean ​marginal bone            
level gain of 2,38±0.92mm​ was observed.  
 
Conclusions: Emdogain ​® has a positive effect on clinical and microbiological outcome           
of non-surgical treatment of peri-implant mucositis. Combined with grafting materials,          
it seems to improve bone fill after surgical treatment of peri-implantitis. More studies             
are necessary to determine the effects of ​Emdogain ​® alone in the clinical outcome of              
peri-implantitis treatment.  
 
Keywords: Peri-implant diseases, non-surgical, surgical, treatment, ​Enamel matrix        
derivative, Emdogain​® 
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ABBREVIATION LIST 
 
BOP - ​Bleeding on Probing 
CCT - ​Controlled clinical trial 
EDTA - ​Ethylenediamine tetra-acetate 
EMD - ​Enamel matrix derivative 
HOMIM - ​Human Oral Microbe Identification Microarray 
IL-6 - ​Interleukin-6 
IL-17 - ​Interleukin-17 
MSM - ​Micro-spherical minocycline 
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I. INTRODUCTION 
 
Dental implants have become a highly predictable option to rehabilitate, partially or            
fully, edentulous patients (Balshi et al., 2015; Chappuis et al., 2013). 
Nonetheless, they are not free from complications. Being the most common           
complications, the biological ones, which are defined as peri-implant diseases -           
peri-implant mucositis and peri-implantitis (Derks et al., 2016). In the 2017 World            
Workshop on the Classification of Periodontal and Peri-Implant Diseases and          
Condition, Caton et al. (2018) described peri-implant diseases as         
infectious/inflammatory diseases that affect the soft as well as hard tissues around a             
functioning implant.  
The clinical manifestations of peri-implant mucositis are bleeding on probing,          
increased peri-implant probing depth and suppuration. For peri-implantitis, loss of          
supporting bone has to be added to the same clinical factors (Zitzmann & Berglundh,              
2008). 
From a biological point of view, both periodontal and peri-implant inammatory states            
are characterized by a dysbiosis with enrichment of anaerobic, Gram negative bacterial            
species (Roberts & Darveau, 2015) with the same key bacteria association (Kumar et             
al., 2012; Leonhardt et al, 1999; Mombelli & Decaillet, 2011;; Persson & Renvert,             
2014; Zhuang et al., 2016). 
Furthermore, it has been shown that peri-implant diseases follow the same pattern than             
gingivitis and periodontitis, in other words, peri-implant mucositis is a precursor of            
peri-implantitis, but with a non-linear, accelerated progression pattern ​(Derks et al.,           
2016). ​Therefore, a treatment of this inflammatory state should be attempted without            
delay once diagnosed. 
Heitz-Mayfield & Lang (2010) demonstrated that biofilm maturation and a susceptible           
host response are the main etiological factors of periodontitis and peri-implantitis.           
Nevertheless, the rate of progression of the peri-implant diseases may be explained by             
differences in the host response of these two infections. 
Several risk factors have been proposed for the development and progression of            
peri-implant diseases. Recently, Schwarz et al. (2017) observed that major risk factors            
for peri-implant diseases include poor bacterial plaque control skills, history of chronic            
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periodontitis, and no regular maintenance care after implant therapy. Others such as            
post-res​torative presence of submucosal cement, lack of peri-implant keratinized         
mucosa and positioning of implants that make it difficult to perform oral hygiene and              
maintenance are potential factors that increase the likelihood of developing          
peri-implantitis.  
The inflammatory state induced by biofilm maturation may result in the loss of             
implant- supporting bone and could finally lead to the loss of the implant (Lindhe &               
Meyle, 2008; Pjetursson et al., 2012; Pjetursson et al., 2014). Esposito et al (1998),              
peri-implant diseases are the etiologic factor for the failure of 10% to 50% of implants               
at least one year after loading. In their systematic review, Derks and Tomasi (2015)              
observed that peri-implantitis affected 22% of individuals with dental implants. 
Therefore, decontamination of the implant surface and resolution of the inammatory           
process are the clinical endpoints of the treatment of peri-implantitis (Serino & Ström,             
2009)​. ​Since peri-implant diseases and periodontitis share the same etiological factors,           
the same therapeutic approach has been advocated (Heitz-Mayfield & Lang, 2010;           
Meffert, 1996; Renvert et al., 2008; Renvert et al., 2012). Management of peri-implant             
diseases is based on a non-surgical or surgical debridement and decontamination           
followed by ongoing supportive therapy or regeneration of the peri-implant bone defect            
to promote the disease resolution (no bleeding and/or suppuration on probing and            
absence of deep probing pocket depth) and create conditions for patients to maintain             
these results in the long term.  
 
In a literature review, Renvert et al. (2008) observed that mechanical non-surgical            
therapy could be effective in the treatment of peri-implant mucositis lesions, especially            
with the use of adjunctive treatments, including the use of antibiotics, antiseptics, and             
laser. However, in peri-implantitis lesions non-surgical therapy was not found to be            
effective. These results started to be refuted recently though by Mettraux et al. (2016)              
and Nart et al. (2020) which observed promising results. 
Nonetheless, surgical exposure of the implants and the mechanical         
debridement/decontamination of the implant surfaces are still advocated to treat most of            
these lesions. Renvert et al. (2012) shown to be a ​predictable method for treating              
peri-implant disease in the short term. However, complete disease resolution seems to            
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be dependent on the initial bone loss at implants (Serino & Turri 2011). Furthermore, in               
the long-term, supportive periodontal therapy seems to play a crucial role in the             
maintenance of the results (Serino et al., 2015).  
In order to improve the results of the surgical treatment, several protocols have been              
proposed, including the use of bone grafts/bone substitutes with and without           
membranes, and have reported clinical and radiographic improvements (Roos-Jansåker         
et al., 2011; Schwarz et al., 2009; Schwarz et al., 2013; Schwarz et al., 2017). In both                 
non-surgical and surgical approaches, there is not a clear gold standard, and Faggion et              
al. (2014), Heitz-Mayfield & Mombelli, (2014), on their systematic review, concluded           
that the evidence available is insufficient to allow specific recommendations for           
peri-implant diseases treatment. However, Schwarz et al. (2015), in their systematic           
review, found that ​adjunctive products may improve the efficacy of treatments at            
peri-implantitis sites. 
Recently, enamel matrix derivative (EMD) (Emdogain ​®​; Straumann, Basel,        
Switzerland) has been tested as an adjunctive tool in both non-surgical and surgical             
peri-implant diseases treatment. EMD is prepared from porcine enamel matrix and           
consists mainly of amelogenin and ameloblastin (Riksen et al., 2014). It is used for              
various purposes, including periodontal regeneration and root coverage (Cordaro et al.,           
2012; Miron et al., 2016). Indeed, the rationale behind its use in surgical treatment of               
periodontitis is to accelerate wound healing and periodontal regeneration (Bosshardt,          
2008; Esposito et al. 2008; Hammarstrom et al., 1997; Miron et al., 2015). It has also                
been demonstrated to have antibacterial properties that inhibit the growth of           
gram-negative bacteria such as ​Porphyromonas gingivalis​, ​Aggregatibacter       
actinomycetemcomitans and ​Prevotella intermedia (Spahr et al., 2002; Walter et al.,           
2006). 
In addition, the results of studies on dogs showed that EMD has a positive effect on                
bone regeneration around the dental implants, especially associated with guided bone           
regeneration (Casati et al., 2002; Ikawa et al., 2019). All of the above-mentioned             
characteristics suggest that enamel matrix derivatives might have a potential added           
value in the treatment of peri-implant diseases.  
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Finally, the aim of this systematic review is to answer the following PICO question: In               
patients with peri-implant diseases (P), the adjunctive use of EMD (I), when compared             
with any treatment protocol without EMD (C) on the non-surgical or surgical treatment             
of peri-implant diseases, adds any benefit in terms of clinical, histological and            
radiographic outcomes (O). 
 
I.1  Material and methods 
 
Protocol development and eligibility criteria 
A protocol was developed and followed the PRISMA (Preferred Reporting Items for            
Systematic Review and Meta-Analyses) statement (http://www.prisma-statement.org). 
 
The focused question was formulated based on the PICOS guidelines: 
1. Population (P) = Humans with peri-implant disease. 
2. Intervention (I) = Non-surgical and surgical treatment for peri-implant diseases with            
EMD (Emdogain​®​). 
3. Comparison (C) = Comparison results of the interventions included in the selected             
literature. 
4. Outcome (O) = Clinical results: implant survival, probing depth (PD) reduction,            
bleeding on probing (BOP), ​bone level, soft tissue gain, ​local plaque index, whole             
mouth plaque index. Microbio ​logical results: ​P. gingivalis​, Interleukin-6 and         
Interleukin-1 counts, HOMIM (Human Oral Microbe Identification Microarray),        
Microbiota characterization. 
5. Study design (S) = Randomized clinical trials (RCT), controlled clinical trials (CCT),             
cohort studies or ​clinical trials. 
 
Search Strategy 
An electronic search of three databases, PubMed, Scopus and Cochrane, was performed            
until 30 of April of 2020. The articles were included if, after full text reading, were                
referring peri-implant mucositis, peri-implantitis, non-surgical or surgical treatment        
with Emdogain​®  
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Search terms 
The electronic search strategy included terms related to the intervention and used the             
following combination of keywords: ((Emdogain OR EMD OR (Enamel matrix          
derivative)) AND (Peri-implantitis OR (Peri-implant diseases) OR (peri-implant        




1. Randomized controlled clinical trials, controlled clinical trials, ​cohort studies or           
clinical trials. 
2. Studies focused on the non-surgical or surgical treatment of peri-implant diseases            
with the use of EMD (Emdogain​®​). 
 
Exclusion criteria 
In vitro and animal studies, case series, case reports, and studies not meeting all              
inclusion criteria. 
 
Screening and selection of studies 
Publication records and titles identified by the electronic search were screened based on             
the inclusion criteria. A second selection was made by screening the abstracts.            
Therefore, full texts of the selected articles were obtained. Then, articles that met the              
inclusion criteria were processed for data extraction. All screening and selection were            
made by two independent researchers (X.B. and T.R.A). 
 
Assessment of risk of bias 
The methodological quality of RCT and CCT studies were assessed guided by the             
Cochrane Handbook. Each study was classified into the following groups: low risk of             
bias if all quality criteria were judged as “present,” moderate risk of bias if one or more                 
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II. RESULTS 
Search 
Figure 1 depicts the flow chart summarizing the results of the search. The electronic              
search rendered 111 potential references in PubMed, 61 in Scopus and 27 in Cochrane.              
After duplicates discarded, titles and abstracts revision, 22 articles were selected for            
full-text screening. At the end of the process, 7 articles were selected for data              
extraction regarding the selection’s criteria of this literature review.  
 
Risk of Bias in Individual Studies 
No single RCT assessed with Cochrane Handbook demonstrated low risk of bias for all              
the criteria and the majority of studies showed a moderate risk of bias (Table 1). Most                
of them provided a detailed report about randomization but not regarding other key             
domains such as allocation concealment and blinding of the participants, thereby           
increasing the potential risk of bias. ​Faramazi et al. (2015), Isehed et al. (2016) and               
Isehed et al. (2018), have an unclear risk of bias. Kashefimehr et al. (2017) has a high                 
risk of bias. 
 
II.1 Non-Surgical Treatment Results 
 
Description of selected studies 
Table 2 depicts the methodological characteristics of the selected studies. Two           
randomized clinical trials, ​Faramarzi et al., 2015; Kashefimehr et al,. 2017, have            
compared the outcomes of a non-surgical treatment of peri-implant diseases with and            
without EMD. Faramarzi et al., 2015 has also made the comparison with the use of               
micro-spherical minocycline (MSM) in a third group. 
All studies included healthy subjects with Peri-implant mucositis and\or mild          
peri-implantitis. Smokers were excluded. The mean age was 47,71±2.17. The number           
of included patients were 64 (Faramarzi et al., 2015) and 41 (Kashefimehr et al., 2017).               
The two studies had a follow-up of 3 months. Both of them used a non-surgical               
mechanical debridement with ultrasonic device and glycine-based powder air-polishing         
to remove subgingival biofilm of the affected site before the EMD application.            
However, Kashefimehr et al., 2017, waited two weeks after the mechanical           
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debridement before using ethylenediamine tetra-acetate (EDTA) to decontaminate the         
implant and placing after the EMD in the affected sites. All the implants in the study of                 
Faramarzi et al. (2015) were of the same brand (Dentis) with absorbable blasted media              
surface treatment.  
 
Clinical results 
None of the two RCT studies reported implant loss during the 3-month follow-up. Both              
of them examined the clinical benefits of EMD in terms of BOP reduction and PD               
reduction, both with statistically ​significant positive adjunctive effects (Table 2). BOP           
was reduced by 50% and PD was reduced by 1.5mm compared with the control group.               
Regarding local plaque index score and the whole mouth plaque index score, both were              
reduced in the EMD and the Control group but without statistically significant            
difference between the two groups (p=0.33 and p=0.734 respectively) (Kashefimehr et           
al., 2017). 
 
Microbiological and inflammatory results 
The two included studies did not evaluate the same microbiological outcomes;           
therefore, the comparison is not possible. Nonetheless, the reduction of ​P. gingivalis            
counts was found significantly greater in the EMD group than the control group after 3               
months (p=0.026) (Faramarzi et al., 2015). In addition, the reduction of Interleukin-6            
(IL-6) and Interleukin-17 (IL-17) has also been observed significantly higher in the            
EMD group than in the control group (p=0.08 and p=0.002 respectively) (Kashefimehr            
et al., 2017) 
 
II.2 Surgical Treatment results 
 
Description of selected studies 
Table 3 depicts the methodological characteristics of the selected studies. ​A total of             
five studies, two RCT and three prospective cohort studies, ​were selected for data             
extraction regarding the selection’s criteria of this literature review. One RCT study,            
Isehed et al., 2018 is actually the follow up of the other study from the same group,                 
Isehed et al., 2016, and one cohort study, Froum et al., 2015, is the continuity of the                 
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previous cohort study, Froum et al., 2012 with the addition of 62 new patients. All               
studies included healthy subjects with peri-implantitis with PD ≥ 4mm. Smokers were            
included except in one cohort study (Mercado et al., 2018). In total, from the 159               
patients included in those studies, 145 were treated with EMD and only 14 without              
EMD. The implants treated consisted of various types and specifications, knowing that            
most of them were titanium micro-rough surface implants from different manufacturers           
such as Biomet 3i, Nobel Biocare, Straumann, and AstraTech. Isehed et al., 2016;             
2018, however did not give any information regarding the dental implants included.  
The two RCT studies, Isehed et al., 2016; 2018 have compared the outcomes of              
peri-implant diseases treatment with and without EMD after the surgical debridement           
and surface decontamination of the affected sites at 1, 3 and 5 years.  
The tree cohort studies, Froum et al., 2012; Froum et al., 2015 and Mercado et al.,                
2018, used EMD in peri-implant diseased sites. The follow-up of these studies varies             
between 2 and 10 years.  
All studies have used a surgical debridement and surface decontamination of the            
affected implants, but it is important to note that the protocols used were very different​.               
For example, the use of tetracycline and air-powder abrasive with sodium bicarbonate            
powder has been reported in two studies (Froum et al., 2012; Froum et al., 2015) and                
EDTA in on other one (Mercado et al., 2018). Besides, some studies used EMD with               
the addition of other regenerative material: xenogeraft and connective tissue graft           
(Froum et al., 2012; Froum et al., 2015 and Mercado et al., 2018) and platelets derived                
growth factor (Froum et al., 2012; Froum et al., 2015). Regarding maintenance care             
programs after treatment, all the studies focused on oral hygiene reinforcement and            
mechanical debridement with specific tools, including curettes, scalers and ultrasonic          
devices. However, in three studies, (Froum et al., 2012; Froum et al., 2015 and              
Mercado et al., 2018), additional surgical procedures, and systemic antibiotics, if           
required, were administered.  
Due to the high heterogeneity within the studies, a meta-analysis was not feasible. 
 
Clinical results 
Out of a total of 215 implants treated with EMD in 145 patients, 2 were lost at 6                  
months post-surgery (Froum et al., 2015), 2 at 12 months (Isehed et al., 2016) and 2 at                 
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5 years (Isehed et al., 2018), yielding a 97.67% survival rate. However, it should be               
noted that in the RCT study, Isehed et al. (2018), no statistically significant differences              
in survival rate were found between the EMD group (69%) and the control group              
(42%) (p=0.48).  
The marginal bone level gain, radiographically calculated, was higher in the cohort            
studies using EMD in combination of xenogenic bone mineral craft (Froum et al., 2012;              
Froum et al., 2015; Mercado et al., 2018) with a mean of 2,38±0.92mm. In the RCT                
study using only EMD, Isehed et al., 2016 and Isehed et al., 2018, the mean bone level                 
gain was 1.4mm at the end of the 5 years follow-up. Furthermore, the latter studies               
have shown no significant difference between surgical treatment with EMD (1.4mm)           
and without EMD (1.3mm) regarding this outcome (p=0.90).  
Bleeding on probing was significantly reduced in the cohort studies (Froum et al.,             
2012; Froum et al., 2015 and Mercado et al., 2018) with a mean of 87.1% reduction.                
Isehed et al., 2018, find a BOP reduction of 44,4% in the EMD group and 60% in the                  
non-EMD group at 5 years.  
Similar results regarding PD reduction can be observed. A mean of 5,17±3.7mm            
reduction in the cohort study (Froum et al., 2012; Froum et al., 2015 and Mercado et                
al., 2018) and 2.8mm in the EMD-group in the RCT study (Isehed et al., 2016). In this                 
last study, no statistically significant difference between the surgery with or without            
EMD has been found (p=0.270) 
A soft tissue gain in Froum et al., 2012 and Froum et al., 2015 of 1,1±0.14mm and                 
0,52±1.44mm respectively has been measured, knowing that both studies have used           
connective tissue graft in addition of EMD. Without a connective tissue graft, Mercado             
et al., 2018 has seen no significant soft tissue gain at 5 years of follow-up (0.6mm;                
p>0.05).  
Regarding the full mouth plaque score and the full mouth bleeding score, the RCT              
studies, Isehed et al., 2016, did not observe any significant difference between EMD             
and non-EMD group (p=0.297 and p=0.347 respectively) 
 
Microbiological results 
Only the RCT study Isehed et al., 2016 examined the biological impact of a surgical               
treatment of peri-implant diseases with EMD. The microbiota of the subgingival           
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biofilm was characterized by the HOMIN microarray       
(http://mim.forsyth.org/homim.html) which analyses the presence of more than 300         
oral bacteria. This resulted in a decrease from 106 species/phylotypes to 94            
species/phylotypes among the 2-week follow-up both in EMD and non-EMD group.           
However, at the 12-month follow-up, the numbers increased and reached pre-treatment           
levels. There was no significant difference between the two treatments at any follow-up             
occasion. However, the statistical tool partial least square (PLS) modelling identified a            
higher prevalence of Gram-positive/aerobic bacteria over the entire follow-up period in           




III.1 Principal findings 
The results of this systematic review, based on the data extraction of the 7 publications               
that corresponded to the selection’s criteria, indicate a high variability in terms of             
treatment protocols, supportive care, follow-up and on how the outcomes were           
reported, therefore a ​meta-analysis was not feasible​. Moreover, no RCT studies           
included in the review are exempted of bias, so the results should be interpreted with               
caution. The scientific evidence regarding the clinical and microbiological performance          
of EMD in conjunction with non-surgical and surgical treatment of peri-implant           
diseases are promising but still limited.  
 
Clinical outcomes 
Regarding the non-surgical treatment of peri-implant mucositis or mild peri-implantitis          
with EMD, Kashefimehr et al. (2017), found that EMD combined with mechanical            
debridement significantly reduced PD (1.5mm) and BOP (-50%) after 3 months, while            
no significant improvement was obtained in areas treated with non-surgical treatment           
alone (p<0.001). Faramarzi et al. (2015), confirmed these results, however the           
improvement in clinical parameters was similar with the adjunctive use of EMD or             
MSM. Those findings are higher than the one observed by Sahm et al. (2011), who               
obtained a smaller PD reduction (​0.6±0.6 and 0.5±0.6) ​, 3 months after the mechanical             
treatment of mild to moderate PI by using only an air-abrasive device with amino acid               
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glycine powder or using carbon curettes and antiseptic therapy with chlorhexidine; and            
Renvert et al. (2009) in mild cases of PI with non-surgical debridement (titanium hand              
instruments or ultrasonic device) after 6 months (mean PD reduction of 0.2mm). It             
suggests that EMD, as an adjunctive to non-surgical treatment of peri-implant           
mucositis, has a positive effect on clinical outcome. Comparative studies with other            
adjuvant, other than MSM, would be interesting.  
Regarding surgical treatment of peri-implantitis, in the RCT study included in this            
review, Isehed et al. (2018), 31% of implants treated with EMD and 58% treated              
without EMD were lost due to reinfection. No statistical difference was observed            
(p=0.48). These implants lost percentage seems very high compared with the one found             
in the cohort studies included in the present review (Froum et al. 2012; Froum et al.                
2015; Mercado et al. 2018). Indeed, on the 200 implants treated with EMD, only 2               
implants were lost at 6 months post-surgery (Froum et al., 2015) yielding a percentage              
of 0.01. However, using the statistical tool PLS modelling, Isehed et al. (2018), found              
that adjunctive EMD was associated with implant survival, BOP and PD reduction. 
We can observe the same disparity between RCT studies and cohort studies regarding             
other clinical outcomes. Froum et al. (2012; 2015) and Mercado et al. (2018) reported a               
higher mean marginal bone level gain (1.77±1.99mm and 4.6±0.73mm, respectively),          
PD reduction (4.6±0.73mm; 5.1±2.2mm) and BOP reduction (73.3% and 91.10%)          
while Isehed et al. (2016; 2018) observed a smaller mean marginal bone level gain              
(0.9mm and 1.4mm), PD reduction (2.8mm) and BOP reduction (30% and 44.4%). 
An explanation for these different results may have been the surface decontamination            
protocol used to treat peri-implantitis. Indeed, Froum et al. (2012; 2015) used, in             
addition do manual curettes, air-powder abrasive and topic Minocycline and          
Tetracycline. Marcado et al. (2018) preferred ultrasonic instrumentation and EDTA          
whereas Isehed et al. (2016; 2018), in their RCT studies, used only ultrasonic             
instrumentation. Based on previous reviews, (Heitz-Mayfield et al., 2014; Suarez et al.,            
2013; Valderama et al. 2013), no decontamination protocol seems to be more effective             
than others and so cannot explain the heterogeneity of clinical outcome observed in this              
systematic review.  
To promote wound healing and regenerative tissue, Froum et al. (2012, 2015), in their              
cohort studies, combined EMD with bone graft and platelet-derived growth factor-BB           
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(PDGF-BB) whereas Mercado et al. (2018) used combined osteoconductive         
deproteinized bovine bone mineral with 10% collagen (DBBMC) and Doxycycline.          
The purpose of using a bone graft is to fill the intrabony defect around the implant with                 
peri-implantitis. A recent meta-analysis about the efficacy of reconstructive surgical          
therapy of peri-implantitis, written by Tomasi et al. (2019), shows a mean PD reduction              
of 2.8mm at 12 months, based on 13 studies. Nonetheless, in the cohort studies              
included in this review, PD reduction was between 5.1±2.2mm and 5.4±0.5mm. This            
difference could be explained by the ability of PDGF-BB to improve bone fill in              
periodontitis treatment (Khoshkam et al., 2015; Nevins et al., 2005) as well as EMD              
capacity to stimulate proliferation and differentiation of osteoblasts (Li et al., 2017;            
Schwartz et al., 2000) and wound healing (​Miron et al., 2015​). The differences in              
clinical outcomes between the cohort studies (Froum et al., 2012; Froum et al., 2015;              
Mercado et al., 2018) and the RCT studies by Isehed et al. (2016; 2018), who used only                 
EMD without any grafting material, may suggest that EMD alone has less capacity to              
improve surgical treatment of peri-implantitis than when combined with other bone           
filling adjunctive material. Moreover, Isehed et al. (2016, 2018) was not able to present              
any statistically significant difference of marginal bone level gain and PD reduction            
between the group treated with EMD alone and the control group at the end of               
follow-up time.  
The type and frequency of supportive care after treatment may be as well, a factor of                
the results heterogeneity. In fact, Froum et al. (2012; 2015) and Mercado et al. (2018),               
in their cohort studies, enrolled patients in supportive periodontal treatment every week            
to every 6 months with the possibility of additional surgical procedure if required.             
Mercado et al. (2018) observed a BOP recurrence in 50% of treated implants at              
12-month follow-up without peri-implant maintenance for 6 months. This percentage          
dropped at 20% after resuming a supportive treatment protocol. ​We might suspect that             
the different supportive therapy used in the studies included in this review had an              
impact on their long-term clinical outcomes. 
 
Microbiological and inflammatory outcomes 
As in periodontal diseases, biofilm is the main etiologic factor of peri-implant diseases             
(Mombelli et al., 1987). In 2014, Persson and Renvert compared the biofilm of healthy              
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implant sites and peri-implantitis sites and found it was associated with higher counts             
of 19 bacterial species, including ​Porphyromonas gingivalis (Persson & Renvert,          
2014). ​P. gingivalis is an anaerobic Gram-/negative anaerobic bacteria species with           
different virulence factors which can invade host cells, induces an inflammatory           
response and destruction of extracellular matrix and bone and induce peri-implantitis           
(Holt et al., 1999). The main outcome of one study included in this systematic review,               
Faramarzi et al. (2015), was changes in the counts of ​P. gingivalis. ​It showed a               
decrease of these bacteria after treatment, with a higher reduction on the EMD group              
than the control group at two-week and three-month intervals. The inhibitory effect of             
EMD on the growth of Gram-/negative periodontal pathogens such as ​P. gingivalis            
(Spahr et al., 2002) could explain this result. But it should be added that Faramarzi et                
al. (2015), have observed the same decrease with the use of MSM, which is consistent               
with a previous study (Renvert et al., 2006). ​In the RCT study, Isehed et al. (2016)                
observed a microbiological difference between the EMD group and the control group, 2             
weeks and 3 months after treatment, however, at 12-month follow-up this difference            
was not relevant. Nevertheless, with the use of statistical tool PLS modelling,            
microbiota from EMD-treated implants were statistically associated with more         
Gram+/positive bacteria over the follow-up period, whereas no EMD-treated         
microbiota was characterized by more Gram-/negative bacteria commonly found in          
peri-implantitis. More Gram+/positive were statically associated with higher        
diminution of BOP and PD, even though it was not observed clinically. The author              
suspects that all these findings emphasize the important role of using an ​antibacterial             
adjuvant for both surgical and non-surgical treatment of peri-implant diseases.  
In the RCT study, Kashefimehr et al. (2017), emphasize the significantly decreased            
amount of IL-6 and IL-17 in the EMD group as compared to the control group. IL-6 is                 
an interleukin which plays a role in the immune response and stimulates Th17 cells to               
produce IL-17 leading to activation of osteoclasts and bone loss along with IL-1β and              
TNF-α (Koh et al., 2007). Based on a meta-analysis, the release of IL-1β was reported               
to be significantly increased at mucositis and peri-implantitis sites, when compared           
with healthy implant sites (Faot et al., 2015). The decreased amount of IL-6 and IL-17               
suggest that EMD may play a role in controlling the inflammatory state of peri-implant              
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disease areas, helping reduce BOP and PD, by diminishing pro-inflammatory cytokines           
and regulating the immune system. 
 
III.2 Confounding factors 
Local factors may influence the outcome of peri-implant diseases treatment: implant           
placement/positioning; prosthesis design; presence of keratinized mucosa; implant        
surface and design; osteo defect configurations. 
It has been previously demonstrated that inadequate access for oral hygiene due to             
prosthesis design/contours was related to the presence of peri-implantitis (de Tapia et            
al., 2019). It is also important to consider access for adequate local plaque control after               
the peri-implantitis has been treated, which highlights the importance of supportive           
care. The studies included in this review present a heterogeneity regarding the            
prosthesis supported by the implant, like crowns, bridges and overdentures and           
placement/positioning which could have an impact of clinical outcome after treatment           
as well as clinical registration of PD. In addition, the sensitivity and standardization of              
assessing bone gain from radiographs might not be optimal. Inherent measurement           
variability in the radiographs should be considered. Furthermore, in three studies           
included in this review, Froum et al., 2012; Froum et al., 2015 and Mercado et al.,                
2018, was performed as a connective tissue graft, if needed, to maximize the amount of               
keratinised tissue. The absence of an adequate band of keratinized peri-implant mucosa            
has been suggested to have a negative influence on treatment outcomes due to             
discomfort when performing oral hygiene resulting in increased plaque accumulation          
(Roccuzzo et al., 2016). The studies present in this review included a variety of implant               
designs and surfaces and ​it has been previously reported that it can influence the              
outcomes of surgical therapy of peri-implantitis (Carcuac et al., 2017; Roccuzzo et al.,             
2017). 
Another factor that influences treatment outcomes is the severity of bone loss and             
defect configuration. In this review, Faramazi et al. (2015) and Kashefimehr et al.             
(2016) reported a bone loss of less or equal to 2mm at baseline before treatment; a                
mean of 5.1mm±1.1mm and 3.8mm±2.28mm in Froum et al (2011; 2015); 5.6mm in             
Isehed et al. (2016; 2018) and 6.92mm±1.26mm for Mercado et al. (2018)            
demonstrating a high heterogeneity of defect configuration. Initial bone loss and           
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different defect configurations that may increase the difficulty of an adequate           
debridement, which in turn, has been suggested to influence the healing (Roccuzo et al.,              
2016; Schwarz et al., 2010) 
 
III.3 Limitations of the review 
The low number of RCT currently available, small subject number; high or unclear risk 
of bias in most of the included studies; heterogeneity in methodologies and treatment 
modalities among studies and wide variation in terms of follow-up periods. Finally, no 
study compared the impact of EMD alone combined with non-surgical debridement to 




Based on studies with a rather limited statistical power, the present systematic review             
suggests that:  
- EMD has a positive effect on clinical outcome of non-surgical treatment of             
peri-implant mucositis.  
- EMD combined with grafting materials seems to improve bone fill after surgical             
treatment of peri-implantitis. 
- There is still a lack of evidence regarding the effects of EMD alone in the clinical                 
outcome of peri-implantitis treatment. 
- EMD has a positive effect on the diminution in the counts of ​P. gingivalis and the                 
inflammation state of peri-implant mucositis sites.  
Furthermore, better designed randomized clinical trials are needed to clearly          
demonstrate and understand the potential role of EMD on the outcomes of non-surgical             
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